patent.fyi
Applications  /  US 2026/0355332
United States Patent Application Publication

US 2026/0355332 A1

Published
Nov 12, 2026
Filed
Jul 13, 2023
Earliest date on the face
Jul 14, 2022
Classification
A61K 47/68037
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Drug enclosed in a liposome

What ifWhat if a liposome carried the drug in its aqueous core and displayed the antibody on its surface?
Claim language“formula XV”

A phospholipid bilayer encloses the drug, and a lipid anchor holds the antibody on the outer surface. The antibody binds a cell-surface antigen, and lysosomal degradation of the internalized liposome releases the drug.

1.2Conjugate in a sugar glass

What ifWhat if the conjugate were supplied in a freeze-dried sucrose matrix as its original molecular form?
Claim language“a pharmaceutically acceptable salt thereof”

Freeze-drying a conjugate solution containing sucrose produces an amorphous solid that limits molecular mobility during storage. Water dissolves the matrix and reconstitutes the conjugate for administration.

1.4Folate receptor targeting

What ifWhat if a folate ligand directed the drug to cells that express a folate receptor?
Claim language“an anti-NaPi2b antibody”

A covalent linker joins the folate ligand to a cytotoxic payload. Cell-surface folate receptors bind the ligand and internalize the conjugate, and cleavage of an acid-sensitive bond in the endosome releases the payload.

1.6Metal isotope delivers radiation

What ifWhat if the payload were a radioactive metal ion held by an antibody-bound chelator?
Claim language“a bioactive molecular fragment”

A macrocyclic chelator attached to the antibody coordinates a beta-emitting lutetium ion. The antibody binds its target, and beta particles emitted by the ion deposit energy in nearby tissue.

1.7Direct attachment at a cysteine

What ifWhat if the release module attached directly to a surface-exposed antibody cysteine?
Claim language“an extension unit”

A haloacetamide group on the release module reacts with the cysteine thiol to form a thioether. After cellular uptake, cleavage within the release module liberates the payload.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Reference reagent for renal toxicology

Use the anti-NaPi2b conjugate with its bioactive payload as a reference reagent in an ex vivo renal toxicology assay. Apply the conjugate to the apical side of polarized renal epithelial cultures with measured surface NaPi2b expression. Measure uptake by antibody staining and compare viability with cultures exposed to the free payload or the unconjugated antibody.

Component substitution

Glucuronide trigger for payload release

Replace the L3 peptide with a beta-D-glucuronide trigger linked to a para-hydroxybenzyl spacer at L4. Connect the antibody-side linker through a pendant handle on the spacer and attach an amine-bearing payload through a benzylic carbamate. Lysosomal beta-glucuronidase removes the glucuronide and exposes the phenol, which initiates spacer fragmentation and releases the payload.

Discrete polyethylene glycol extension unit

Replace L1 with a discrete polyethylene glycol spacer containing eight ethylene oxide units. Place a maleimide at the antibody-facing end for coupling to an exposed antibody cysteine and an amine at the distal end for amide coupling to a carboxyl-bearing L2 connector. Position the L3 peptide and the L4-payload assembly downstream of L2.

Parameter or scale variation

Matched mean with different loading distributions

Prepare two conjugate preparations with the same antibody, linker, and payload. Use hydrophobic interaction chromatography to collect species bearing two, four, and six payloads per antibody, and verify each fraction by intact mass spectrometry. Use the four-payload fraction for one preparation and blend the two- and six-payload fractions at a one-to-one antibody molar ratio for the other, giving both preparations a mean loading of four.

Combination with existing systems

Conjugate dosing in a perfused chip

Integrate the conjugate with a two-channel microfluidic culture system that separates a perfused endothelial channel from a chamber containing NaPi2b-positive tumor spheroids. Deliver the conjugate through the endothelial channel and collect outlet samples at fixed intervals. Measure intact conjugate and released payload in the outlet and image the spheroids to track antibody penetration and cell death.

Automated or data-driven variant

Automated pooling by measured drug loading

Connect a hydrophobic interaction chromatography system to an automated fraction collector and analyze collected fractions by intact mass spectrometry. Software calculates mean drug loading for each fraction from the relative abundances of the resolved loading species. The software combines these measurements with protein concentrations to select pooling volumes that meet a specified mean loading and a maximum allowable fraction of unconjugated antibody.

Specific version of a part

Two payloads per antibody

One engineered cysteine on each heavy chain provides two conjugation sites per intact antibody. A thiol-reactive linker attaches one payload at each site, and intact-mass spectrometry measures the occupancy distribution.

Payload inhibits microtubule assembly

A synthetic peptide-derived tubulin inhibitor carries an amine that forms a carbamate with the linker. Intracellular linker cleavage releases the inhibitor, which binds tubulin and suppresses microtubule polymerization.

Short polyethylene glycol extension

A spacer with four ethylene glycol repeats separates the antibody attachment site from the downstream linker units. The ether oxygens hydrate the spacer, and functional groups at both ends provide covalent attachment points.

Triazole joins linker segments

An azide on the extension unit reacts with a terminal alkyne on the adjoining linker segment in a copper-catalyzed cycloaddition. The resulting 1,2,3-triazole forms a covalent connection between the segments.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2018/0228918 A1
Published
Aug 16, 2018
Filed
Jan 20, 2016
Class
A61K 47/6923
Document BUS 2021/0230218 A1
Published
Jul 29, 2021
Filed
Oct 23, 2019
Class
C07K 5/06191
Claim 1
Document A
Document B
1.1TbL1-L2-L3-L4-D]q formula XV
The silica-based biomolecule carrier comprises a porous core; a first bioactive moiety; a second bioactive moiety functionally associated with the first bioactive moiety; and linkers for respectively conjugating the first bioactive moiety and the second bioactive moiety to the porous core.
A · US 2018/0228918 A1 · abstract
The three components (an antibody, a cytotoxin and a linker) of an ADC constitute a targeted drug delivery system, in which the construction and optimization of linkers are crucial for the development of such system.
B · US 2021/0230218 A1 · ¶ 2
1.2or a stereoisomer of the antibody-drug conjugate, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof,
1.3wherein:
1.4Tb is an anti-NaPi2b antibody or an antigen-binding fragment thereof,
The first bioactive moiety and the second bioactive moiety are different from yet functionally associated with each other and may be independently selected from an enzyme, an antibody, a catalytic mimetic, a ligand, a hormone, a biomolecule-binding protein, and a functional fragment thereof, such as a peptide or polypeptide.
A · US 2018/0228918 A1 · ¶ 5
1.5q is a drug-to-antibody coupling ratio;
1.6D is a bioactive molecular fragment;
For example, bioactive moieties may be formed from synthetic, recombinant or isolated peptides and proteins such as antibodies, antigens, synthetic small molecule peptidomimetics, receptor ligands, enzymes, adhesion peptides, nucleotides, polynucleic acids such as DNA and antisense nucleic acid molecule, activated sugars and polysaccharides, and organic drug molecules.
A · US 2018/0228918 A1 · ¶ 20
The product obtained by removing Teoc protection as described above is often used as part of the linker to be covalently linked to the drug moiety in the preparation of antibody-drug conjugate.
B · US 2021/0230218 A1 · ¶ 62
1.7L1 is an extension unit;
1.8L2 is absent or is a connector unit;
In order to achieve covalent linking to the antibody moiety, the said product is often coupled with a connector via the following specific reaction routes:
B · US 2021/0230218 A1 · ¶ 62
1.9L3 is selected from Val-AA1-Gly, Val-AA1, Ala-AA1, Gly-AA1, AA1-Gly, Ala-AA1-Gly, Gly-AA1-Gly, AA1-Ala-Asn, and AA1; the structure of the amino acid residue represented by AA1 is shown as follows:
Among them, oligopeptide linkers (such as valine-citrulline dipeptide (Val-Cit, VC)) have been widely used in various ADC drugs.
B · US 2021/0230218 A1 · ¶ 3

An empty cell means only that no passage was reproduced there.

Statements in these documents
However, due to the limitations of some existing approaches, particularly regarding cellular uptake, targeting and delivery issues, there is a need to explore more satisfactory solutions.
A · US 2018/0228918 A1 · ¶ 4
The two different and functionally-associated biomolecules are thus co-delivered into the cells at the same time.
A · US 2018/0228918 A1 · ¶ 8
However, lower amines are usually used in this method to remove the Fmoc protecting group, so that byproducts are easily formed and hard to completely remove.
B · US 2021/0230218 A1 · ¶ 7
However, transition metal, usually Pd, is required as the catalyst when removing the Cbz protecting group in this method, which is harmful to the human body by resulting in heavy metal residues which is hard to remove.
B · US 2021/0230218 A1 · ¶ 9
Cite aspatent.fyi, US 2026/0355332 A1, claim 1, first published 2026-11-19T10:32:39-05:00, https://patent.fyi/US20260355332/, SHA-256 01cdcfeb662bb7ff9c99bc1aa4351c80d7c455552b30ecc0d279cbca1bc67f8e
First published
Permanent addresshttps://patent.fyi/US20260355332/
Content fingerprint (SHA-256)01cdcfeb662bb7ff9c99bc1aa4351c80d7c455552b30ecc0d279cbca1bc67f8e
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi